Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience

Introduction: Aflibercept in combination with FOLFIRI has been shown to improve overall survival in the pivotal VELOUR study. Aflibercept has not yet been marketed in India. Sanofi has made available this drug for Indian patients under a program called Named Patient Access Program (NPP). We present...

Full description

Bibliographic Details
Main Authors: Govind Babu, Umesh Das, Kuntejowdahalli Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Journal of the Scientific Society
Subjects:
Aflibercept
colorectal cancer
FOLFIRI
Online Access:http://www.jscisociety.com/article.asp?issn=0974-5009;year=2016;volume=43;issue=3;spage=140;epage=143;aulast=Babu

Internet

http://www.jscisociety.com/article.asp?issn=0974-5009;year=2016;volume=43;issue=3;spage=140;epage=143;aulast=Babu

Similar Items